Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial
Author(s) -
Takao Fujisawa,
Terufumi Shimoda,
Keisuke Masuyama,
Kimihiro Okubo,
Kohei Honda,
Mitsuhiro Okano,
Toshio Katsunuma,
Atsuo Urisu,
Yasuto Kondo,
Hiroshi Odajima,
Kazuyuki Kurihara,
Makoto Nagata,
Masami Taniguchi,
Shoichiro Taniuchi,
Satoru Doi,
Tomoshige Matsumoto,
Shoji Hashimoto,
Akihiko Tanaka,
Kensuke Natsui,
Nahoko Abe,
Hideki Ozaki
Publication year - 2017
Publication title -
allergology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.49
H-Index - 58
eISSN - 1440-1592
pISSN - 1323-8930
DOI - 10.1016/j.alit.2017.11.004
Subject(s) - medicine , asthma , adverse effect , allergy , house dust mite , anaphylaxis , clinical trial , anaphylactic shock , allergen immunotherapy , allergen , immunology
To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom